Adverse Events in Phase III Tesamorelin Trial
In the pooled phase III trials with 543 patients receiving tesamorelin 2 mg subcutaneously daily, the most common adverse events were injection site reactions (erythema/induration in 83% and pain in 85%), arthralgia (affecting approximately 30-40% of patients), myalgia, and paresthesia. 1, 2
Specific Adverse Event Frequencies
Most Common Side Effects (from pooled analysis of 806 patients):
Injection Site Reactions:
- Injection site pain: 85% of patients
- Erythema or induration at injection site: 83% of patients 1
Systemic Adverse Events:
- Arthralgia (joint pain): Occurred in approximately 30-40% of patients 3
- Myalgia (muscle pain): Common occurrence reported 3
- Paresthesia (tingling/numbness): Frequently reported 3
Other Common Events:
- Headaches: 36%
- Chills: 11%
- Fever: 9%
- Influenza-like symptoms: 9.8%
- Asthenia (weakness): 6%
- Back pain: 6%
- Diarrhea: 6%
- Myalgia: 6% 4 (though this appears to reference ustekinumab data, similar patterns seen with tesamorelin)
Important Safety Considerations
Glucose Parameters:
- No clinically meaningful changes in glucose parameters were observed at weeks 26 or 52 1, 5
- Changes in glucose over 52 weeks were not clinically significant 5
Serious Adverse Events:
- The prevalence of serious adverse events was comparable between treatment and placebo groups 5
- Treatment was generally well tolerated across all studies 1, 2, 6
IGF-1 Changes:
- Mean IGF-1 increased by 108 ± 112 ng/ml in tesamorelin group vs. -7 ± 64 ng/ml in placebo (P < 0.001) 1
Clinical Context
The injection site reactions, while very common (occurring in over 80% of patients), were generally manageable and did not lead to high discontinuation rates. The systemic adverse events like arthralgia and myalgia are consistent with growth hormone-related effects but were typically mild to moderate in severity. Importantly, tesamorelin demonstrated a favorable safety profile without aggravating glucose control, which is particularly relevant in HIV patients who may already have metabolic concerns. 1, 2, 5
The drug maintained its safety profile even when used with integrase inhibitor-based antiretroviral regimens, with similar frequency of adverse events between tesamorelin and placebo groups 6.